Why Is BioAge Labs Stock Sinking Friday?
Neumora Therapeutics Inc NMRA
$1.61
▼ -2.42%
($-0.04)
📅 Earnings This Week
Open
$1.56
Prev Close
$1.65
Day Range
$1.48 – $1.61
52W Range
$0.83 – $3.65
Market Cap
$298.31M
Beta
2.84
EPS (TTM)
$-1.33
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-09-15 |
| Shares Out. | 185,280,000 |
| Website | neumoratx.com/ ↗ |
| Phone | 18577600900 |
| Employees | 92 |
| Net Income | -$53.5M |
| Free Cash Flow | -$193.4M |
| Total Assets | $153.9M |
| Total Liabilities | $83.2M |
| Equity | $70.7M |
About Neumora Therapeutics Inc
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Neumora Therapeutics Inc is a publicly traded company under the ticker symbol NMRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)